Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Fluorouracil and Calcipotriene for Actinic Keratoses
NCT07794059Phase 1Not yet recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluorouracil 5% cream and calcipotriol in actinic keratosis (AK) (3 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Percent change from baseline in total Actinic Keratoses at 9 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
fluorouracil 5% creamcalcipotriol
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT07794059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794059.